Abstract: Objective  To observe the efficacy and safety of low-dose argatroban in the treatment of patients with acute ischemic stroke under different etiology.
  Methods  A retrospective analysis of 124 patients with acute ischemic stroke within 48 hours of onset was divided into LAA group according to the Trial of Org 10172 in Acute Stroke Treatment(TOAST) classification of patients with argatroban. In the CE group and the SAO group, 20 mg of argatroban injection was given daily for 7 days after admission, and conventional treatments such as 100 mg of aspirin were combined. The short-term clinical effects were compared before treatment and 7 d, 14 d after treatment with the National Institutes of Health Stroke Scale(NHISS) and Barthel Index(BI) rating scale. The bleeding of digestive tract, skin and mucosa, intracranial and other adverse events during hospitalization were observed.
  Results  After treatment, the NHISS scores of the three groups showed a downward trend, and Bi index showed an upward trend. The change range of CE group was the largest, and there were significant differences among groups, time points and interaction between groups(P＜0.05). The total effective rate of CE group was higher than that of LAA group and Sao group(P＜0.05). There was no significant difference in the incidence of adverse events among three groups(P＞0.05).
  Conclusion  The early combined use of low-dose argatroban in patients with acute ischemic stroke under TOAST etiology can benefit without increasing the risk of bleeding, with CE being the best.

Key words: stroke, TOAST classification, argatroban